BioTech Startup Akribion Raises €8m for Programmable Cell Depletion
Akribion Therapeautics, a Zwingenberg-based BioTech startup developing a RNA-guided, nuclease-based technology for programmable cell depletion, recently announced its exit from stealth and the completion of a Seed financing round raising €8 million to accelerate the development of therapeutics based on Akribion’s proprietary G-dase® E nucleases. The round was led by CARMA FUND and RV Invest,